ArticleACS central science2021
Sialic Acid Ligands of CD28 Suppress Costimulation of T Cells.
Article in ACS central science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 66 citations in OpenAlex.
- Enzyme-mediated remodeling of the extracellular matrix and glycocalyx to enhance immunotherapy in solid tumors.Bioengineering & translational medicine · 2026Review
- α2,6-Sialoglycan-regulated antitumor immunity of tumor-infiltrating CD8Nature chemical biology · 2026Article
- Impact of sialyltransferase deletion in mature T cells on control of subcutaneous and metastatic cancers.Glycobiology · 2026Article
- Immune implications and therapeutic opportunities of tumor glycosylation.Nature cancer · 2026Review
- Article
- HIV-induced sialoglycans on infected CD4+ T cells promote immune evasion from myeloid cell-mediated killing.Nature communications · 2025Article
- Review
- Age-related remodeling of the sialoglycans dampens murine CD8Science advances · 2025Article
- Discovery and characterization of vertebrate sialoglycan-binding proteins.Seminars in immunology · 2025Review
- Targeting Sialidase to PD1 Enhances T cell Function and Tumor Control.ACS central science · 2025Article
- Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence.bioRxiv : the preprint server for biology · 2025Article
- Article
- New insights into the immunomodulatory potential of sialic acid on monocyte-derived dendritic cells.Cancer immunology, immunotherapy : CII · 2024Article
- Glycoengineering in antigen-specific immunotherapies.Current opinion in chemical biology · 2024Review
- Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge.NPJ vaccines · 2024Article
- Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.Cellular & molecular immunology · 2024Article
- Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager.Nature biomedical engineering · 2024Article
- The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.The Journal of biological chemistry · 2024Article
- Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Sialic acids on T cells are crucial for their maintenance and survival.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Effector T cells comprise the cellular arm of the adaptive immune system and are essential for mounting immune responses against pathogens and cancer. To reach effector status, costimulation through CD28 is required. Here, we report that sialic acid-containing glycans on the surface of both T cells and APCs are alternative ligands of CD28 that compete with binding to its well-documented activatory ligand CD80 on the APC, resulting in attenuated costimulation. Removal of sialic acids enhances antigen-mediated activation of naïve T cells and also increases the revival of effector T cells made hypofunctional or exhausted via chronic viral infection. This occurs through a mechanism that is synergistic with antibody blockade of the inhibitory PD-1 axis. These results reveal a previously unrecognized role of sialic acid ligands in attenuation of CD28-mediated costimulation of T cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.